Melbourne-based Telix Pharmaceuticals Ltd (ASX:TLX) has reported that data from recent tests on TLX591 – therapy targeted at treatment of specific forms of prostate cancer – reveal that people can live with the disease without it getting worse for more than eight months after treatment, suggesting strong efficacy of the drug.
TLX591 is described as radio-antibody-drug conjugate (rADC) therapy which aims to treat adults who have PSMA (prostate-specific membrane antigen)-positive metastatic castrate-resistant prostate cancer, or mCRPC.
Telix’s current ProstACT SELECT testing on the therapy involved a sample size of 23 patients who had been previously treated for mCRPC – which was progressive – with these patients receiving two 76 mCi intravenous infusions of TLX591 14 days apart.
This was a follow-up to the company’s previous testing of TLX591 through the ProstACT SELECT trial, which had showed the therapy to have a favourable safety profile and biodistribution.
According to the ProstACT SELECT trial, the reported median radiographic progression-free survival (rPFS) is 8.8 months. This marks the period of time through which patients can live with the illness without it getting worse, once treated with the therapy.
Nuclear Oncologist and General Internal Medicine Physician and lead recruiter onto the SELECT trial Nat Lenzo said the results showed the potential effectiveness of TLX591.
“We are encouraged by this rPFS result, which compares favourably to small molecule radioligand therapy (RLT) Phase I and II studies at similar stages of development,” he said.
“This is a compelling signal of the potential efficacy of TLX591 in this heavily pre-treated population.
“The results further support the development of this candidate in an earlier mCRPC patient population which is the focus of the ProstACT GLOBAL7 Phase III trial and where there remains significant unmet need for effective treatment.”
Telix has been trading at $15.74.